0

Merrimack Continues To Make Progress With Pancreatic Cancer Drug

(BiotechPickList) – Today Merrimack Pharmaceuticals (NASDAQ:MACK) announced that it has initiated a phase 2 trial in patients with metastatic pancreatic cancer. These patients are being directly targeted as an IGF-1 biomarker population. This means that these patients have high levels of… Continue Reading

0

Can-Fite Biopharma Reports Positive Phase 2/3 Results In Patients with Psoriasis

On April 27,  2015 Can-Fite Biopharma (NASDAQ:CANF) reported positive results in a phase 2/3 trial in patients with moderate-severe psoriasis. As soon as the news was announced shares of Can-Fite surged high ending the day up 51.62%. The new data… Continue Reading

0

Alnylam Reports Positive Phase 2 Results In Patisiran Study

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) are up roughly 2% after the company reported positive results in their phase 2 open label extension study –OLE — of Patisiran. This phase 2 trial is treating patients with a disease known as TTR-Amyloidosis,… Continue Reading

0

FDA Approves Amgen’s Corlanor Drug For Heart Failure

Amgen (NASDAQ:AMGN) closed the trading day at $165.47, up 1.78% as the company announced today that the FDA had approved a heart-failure drug known as Corlanor — ivabradine. The drug Corlanor is an all oral type drug that is intended… Continue Reading

0

Regulus And AstraZeneca To Advance Big Potential NASH Drug

Shares of Regulus Therapeutics (NASDAQ:RGLS) surged about 8% in after hours trade today after the company reported that Astrazeneca (NYSE:AZN) wants to advance RG-125 — also known as AZD4076 — for the ability to treat patients with NASH who additionally… Continue Reading

0

Intrexon Partners with Merck Serono on CAR-T Development Deal

Shares of Intrexon Corp (NYSE:XON) soared as much as 8% yesterday after the company had announced that it had formed a collaboration deal with Merck Serono – a German biotechnology company with no relationship to Merck (NYSE:MRK). Intrexon had partnered… Continue Reading

0

RXi Pharmaceuticals Provides Positive Update On Phase 2a Trials And Collaborations

On March 23, 2015 RXi Pharmaceuticals (NASDAQ:RXII) first announced preliminary findings from its phase 2a keloid trial study known as RXI-109-1401. This trial is evaluating  the ability to reduce patients’ recurrence of keloids following keloidectomy. This phase 2a trial is ongoing… Continue Reading

0

Esperion Therapeutics Announces Positive Phase 2b Results In Patients with Hypercholesterolemia

Shares of Esperion Therapeutics (ESPR) are up about 22% after the company reported positive phase 2b results in Hypercholesterolemia. Esperion is using its own drug ECT-1002 which is given to patients in conjunction with these patients taking current Statin therapy.… Continue Reading

0

Acadia Pharmaceuticals Tanks After CEO Retires, and Application To FDA For Parkinson’s Drug Approval Is Delayed

Shares of Acadia Pharmaceuticals (ACAD) tanked about 28% in after hours trading today after the company reported that the CEO will retire and that the New Drug Application — NDA for the company’s Parkinson’s Drug will be delayed. For starters… Continue Reading

0

Orexigen Shares Retreat After Comment From The FDA About Safety Data For Contrave

A few days ago we wrote an article on Orexigen Therapeutics (OREX) about news that the company had achieved positive safety results in a study in addition to slightly improving patients’ cardiovascluar health. Shares of Orexigen had soared big on… Continue Reading